ALPPS对结直肠癌肝转移瘤生长的影响
该研究在小鼠和人类中探讨ALPPS对结直肠癌转移瘤生长的影响。小鼠实验显示ALPPS与门静脉结扎或假手术相比,肝内肿瘤数量、大小、生长动力学及生存期均无显著差异,体外细胞增殖和肺转移进展亦无差异。人类注册数据未发现ALPPS第一阶段后再生阶段未来残肝内肿瘤加速生长。结论认为ALPPS相关的加速再生过程似乎不增强结直肠转移瘤的生长。
要点
- ALPPS不加速小鼠肝内结直肠转移瘤的生长。
- ALPPS与门静脉结扎后小鼠生存期无显著差异。
- 人类数据未显示ALPPS后未来残肝内肿瘤加速生长。
核心结论
- ALPPS相关的加速再生过程似乎不增强结直肠转移瘤的生长。
研究设计与样本
- 研究在小鼠中比较ALPPS与90%门静脉结扎对结直肠肝和肺转移的影响,并通过磁共振成像、组织学和生存实验评估肿瘤进展。
- 体外测试ALPPS、门静脉结扎和对照血清对结直肠癌细胞系MC38和CT26增殖的影响。
- 利用国际ALPPS注册数据库识别ALPPS第一阶段后未来残肝内仍有肿瘤的患者。
主要发现
- ALPPS第一阶段后2周和3周,肝磁共振显示肝内肿瘤数量(P=.14/0.82)、大小(P=.45/0.98)和生长动力学(P=.58/0.68)与门静脉结扎或假手术组相似。
- 第二阶段完成后,ALPPS组与门静脉结扎组肿瘤生长无差异。
- 肿瘤细胞注射后中位生存期:假手术组36天(95%CI 27-57天),完成ALPPS组42天(95%CI 35-49天),门静脉结扎组39天(95%CI 34-43天),P=.237。
- 肺转移进展和体外细胞增殖在各组间相当。
- 人类观察未发现ALPPS第一阶段后再生阶段未来残肝内肿瘤加速生长。
临床怎么用
- 对于结直肠癌肝转移患者,ALPPS的加速再生效应未显示促进肿瘤生长,但需结合个体情况评估。
局限性
- 研究基于小鼠模型和注册数据库观察,人类证据为描述性,未提供详细样本量或统计比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy induces an unprecedented liver hypertrophy and enables resection of otherwise unresectable liver tumors. The effect of associating liver partition and portal vein ligation for staged hepatectomy on tumor proliferation, however, remains a concern. This study investigated the impact of associating liver partition and portal vein ligation for staged hepatectomy on growth of colorectal metastases in mice and in humans. METHODS: The effect of associating liver partition and portal vein ligation for staged hepatectomy and 90% portal vein ligation on colorectal liver and lung metastases was investigated in mice. In vivo tumor progression was assessed by magnetic resonance imaging, histology, and survival experiments. The effects of associating liver partition and portal vein ligation for staged hepatectomy, portal vein ligation, and control sera on cultures of several colorectal cancer cell lines (MC38 and CT26) were tested in vitro. Additionally, the international associating liver partition and portal vein ligation for staged hepatectomy registry enabled us to identify patients with remaining tumor in the future liver remnant after associating liver partition and portal vein ligation for staged hepatectomy stage 1. RESULTS: Two and 3 weeks after associating liver partition and portal vein ligation for staged hepatectomy stage 1, portal vein ligation, or sham surgery, liver magnetic resonance images showed similar numbers (P=.14/0.82), sizes (P=.45/0.98), and growth kinetics (P=.58/0.68) of intrahepatic tumor. Tumor growth was not different between the associating liver partition and portal vein ligation for staged hepatectomy and portal vein ligation groups after completion of stage 2. Median survival after tumor cell injection was similar after sham surgery (36 days; 95% confidence interval; 27-57 days), completion of associating liver partition and portal vein ligation for staged hepatectomy (42 days; 95% confidence interval; 35-49 days), and portal vein ligation (39 days; 95% confidence interval; 34-43 days, P=.237). Progression of pulmonary metastases and in vitro cell proliferation were comparable among groups. Observations in humans failed to identify any accelerated tumor growth in the future liver remnant within the regenerative phase after associating liver partition and portal vein ligation for staged hepatectomy stage 1. CONCLUSION: The accelerated regeneration process associated with associating liver partition and portal vein ligation for staged hepatectomy does not appear to enhance growth of colorectal metastases.
引用
- Kambakamba P, Linecker M, Schneider M, et al. Impact of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) on growth of colorectal liver metastases. Surgery. 2017. PMID: 29248180. doi:10.1016/j.surg.2017.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。